Lifecore Biomedical, Inc. (LFCR)
- Previous Close
6.64 - Open
6.63 - Bid 6.55 x 400
- Ask 8.26 x 200
- Day's Range
6.44 - 6.74 - 52 Week Range
4.13 - 11.46 - Volume
110,906 - Avg. Volume
205,361 - Market Cap (intraday)
201.457M - Beta (5Y Monthly) 1.06
- PE Ratio (TTM)
-- - EPS (TTM)
-2.14 - Earnings Date Apr 29, 2024 - May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
www.lifecore.com459
Full Time Employees
May 28
Fiscal Year Ends
Sector
Recent News: LFCR
Performance Overview: LFCR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LFCR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LFCR
Valuation Measures
Market Cap
201.46M
Enterprise Value
294.99M
Trailing P/E
--
Forward P/E
11.38
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.91
Price/Book (mrq)
--
Enterprise Value/Revenue
2.86
Enterprise Value/EBITDA
-8.94
Financial Highlights
Profitability and Income Statement
Profit Margin
-96.41%
Return on Assets (ttm)
-4.67%
Return on Equity (ttm)
-104.52%
Revenue (ttm)
103.27M
Net Income Avi to Common (ttm)
-64.24M
Diluted EPS (ttm)
-2.14
Balance Sheet and Cash Flow
Total Cash (mrq)
19.09M
Total Debt/Equity (mrq)
505.94%
Levered Free Cash Flow (ttm)
15.96M
Research Analysis: LFCR
Company Insights: LFCR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: LFCR
Daily – Vickers Top Buyers & Sellers for 01/18/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 07/14/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 07/13/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 07/12/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.